The JAMA research letter from University of Michigan investigators (2026) presents important observational data drawn from IQVIA's Longitudinal Prescription Database, which captures 92% of U.S. retail pharmacy fills. Using a validated claims-based definition of long-term opioid therapy (LTOT)—≥90 days of opioids with either 120+ days supply or ≥10 fills in 180 days—the authors document a 24.3% drop in patients receiving LTOT, from 5.6 million in 2015 to 4.2 million in 2023. This large-scale observational analysis (tens of millions of records) benefits from national scope and rigorous sensitivity testing but cannot determine prescribing indications, patient comorbidities, prescriber traits, or actual consumption—limitations the authors explicitly note. No conflicts of interest were reported.

While the source accurately reports the aging cohort (mean age rising from 52.5 to 60.5 years), Medicare's growing dominance (38.8% to 48.7%), falling mean daily dose (47.9 to 38.6 MME), reduced benzodiazepine overlap (43.8% to 33.5%), and rising gabapentinoid co-prescribing (47% to 58.7%), it stops short of connecting these trends to larger patterns. The 2016 CDC opioid guideline and its 2022 update (CDC MMWR 2022;71) successfully reduced excessive initiation and high-dose prescribing yet frequently produced unintended consequences: abrupt tapers associated in multiple observational cohorts with increased overdose, suicide, and mental-health crises. A 2018 BMJ systematic review synthesizing dozens of observational studies (cumulative n>1 million) found only weak evidence for sustained functional benefit from LTOT in chronic non-cancer pain alongside clear dose-dependent risks of dependence, overdose, and fractures.

The coverage also underplays the substitution effect. The sharp rise in gabapentinoid co-prescribing is not necessarily safer; a 2021 JAMA Network Open retrospective cohort (n=1,421,514) documented significantly elevated respiratory depression risk when these agents are combined with opioids, echoing concerns from FDA warnings. Meanwhile, the shift toward older Medicare beneficiaries maps onto the aging baby-boomer population burdened by osteoarthritis and multimorbidity, yet Medicare reimbursement still inadequately covers evidence-based non-pharmacologic options such as intensive physical therapy, cognitive-behavioral pain programs, or interdisciplinary clinics.

Synthesizing these sources with the 2023 Lancet Commission on chronic pain reveals the deeper structural failure: despite hundreds of RCTs demonstrating moderate-to-large effect sizes for multimodal, non-opioid approaches (exercise, CBT, mindfulness, certain antidepressants and anticonvulsants used judiciously), U.S. payment systems, clinician training, and access barriers leave most patients without viable alternatives. The editorial lens is therefore precise—4.2 million Americans on extended opioid therapy in 2023, representing 11.5% of all opioid recipients, signals not merely residual prescribing inertia but a systemic deficit in chronic pain infrastructure. As illicit fentanyl now drives the majority of overdose deaths, the continuing reliance on prescription opioids for a sizable chronic-pain population creates overlapping vulnerabilities: patients facing taper pressure may turn to street supplies, while those maintained on opioids remain at elevated medical risk.

Genuine progress requires more than prescription caps. It demands scaled reimbursement for multidisciplinary pain care, pragmatic trials of novel non-opioid analgesics, expanded access to addiction medicine support for physiologic dependence, and longitudinal research tracking patient-centered outcomes beyond mere fill counts. Until these gaps close, the apparent success in curbing long-term opioid prescribing will remain partial and precarious.